NeoStem to Present at Multiple May and June Conferences

NEW YORK, May 4, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today that the Company's management and experts will present at multiple conferences in May and early June.

Research Seminar Series, Li Ka Shing Knowledge Institute (LKSKI)

World Stem Cells and Regenerative Medicine Congress

  • Date and Time: Wednesday, May 20, 2015, 3:30 PM GMT
  • Venue: Business Design Centre, London
  • Website:
  • Presenter: Dr. Robert Preti, President of PCT, Chief Scientific Officer of NeoStem
  • Topic: Accelerating Time To Market: Development and manufacturing considerations for cell therapy product commercialization

2015 Marcum MicroCap Conference

12th International Symposium on Stem Cell Therapy & Cardiovascular Innovations

  • Date and Time: Thursday, May 28, 2015, 11:18 AM CET
  • Venue: Aula Magna. Pabellón Docente. Hospital Universitario Gregorio Marañón, Madrid, Spain
  • Website:
  • Presenter: Dr. Douglas Losordo, Chief Medical Officer
  • Topic: Cell based therapies to prevent and cure heart failure. More than an adventure?

International Society for Cell Therapy 2015 Annual Meeting

  • Date and Time: Friday, May 29, 2015, 12:45 PM PT
  • Venue: Caesars Palace, Las Vegas, Nevada
  • Website:
  • Workshop Participant: Dr. Jacob Ceccarelli, Biotechnology Engineer, PCT
  • Topic: Corporate Tutorial – Fresenius Kabi

2015 ASCO Annual Meeting

  • Date and Time: Monday, June 1, 2015, 1:15 – 4:15 PM CT
  • Venue: McCormick Place, Chicago, Illinois
  • Website:
  • Presenter: Dr. Robert O. Dillman, Vice President, Oncology
  • Poster: Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (Intus trial)

About NeoStem, Inc.

NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell-based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immuno-oncology, ischemic repair and immunomodulation) with a lead, late-stage clinical program for each. The combination of a rich therapeutics pipeline and an externally recognized in-house center for cell therapy process development and manufacturing has created an organization with unique capabilities for accelerated and efficient product development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 2, 2015, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.

CONTACT: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email:

Source:NeoStem Inc.